ERBB2 and cancer: Based on this prior evidence, the primary aim of this study was to test the association of the HER2-enriched subtype with pCR in a consecutive series of HER2-positive breast cancer patients homogeneously treated with trastuzumab-based neoadjuvant chemotherapy at a single comprehensive cancer center.